The complaint centers on claims that Zoetis violated the Securities Exchange Act of 1934 by issuing false statements to the market. Specifically, the suit alleges the company concealed weakening prescription growth for its Librela medication following FDA warnings regarding neurological complications in dogs. Furthermore, the litigation highlights a loss of market share for the company’s Trio product and its dermatology treatments, Apoquel and Cytopoint, as new competitors entered the space.

Investors who incurred losses during the specified class period are encouraged to contact attorney Brian Schall in Los Angeles to discuss potential participation. The class remains uncertified, meaning shareholders who choose not to act will remain absent class members without legal representation by the firm. The Schall Law Firm continues to gather claimants to pursue recovery for damages sustained when the market adjusted to the disclosed product performance issues.